Statera Biopharma is developing novel immunotherapies to restore immune health through leveraging of complex pleiotropic beneficial effects. Restoring immune homeostasis has the potential to treat many types of diseases. To achieve this, the integration of many components is required. Statera is embracing this complexity through their advanced immunomodulating multi-component system (AIMS) platform, which combines many assays that point to the effect required in vivo. Through their platform, Statera is advancing several late-stage developmental product candidates that includes STAT-200 and STAT-600 for the treatment of certain cancers and inflammatory diseases.

Statera Biopharma

Founded: 2014
Location: Fort Collins, CO
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Pediatric Crohn&#x27;s disease
Drug types: GI, PED, INF, HEM, TOX
Lead product: STAT-201
Funding: $5.7M stock Mar 2022

Drug notes:

About:

Jobs: